

**4basebio PLC**

("4basebio" or the "Company")

**RBC Capital Markets initiates research coverage**  
A

Cambridge, UK, 14 March 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, announces that RBC Capital Markets has initiated research coverage of the Company, which can be found on the Company's website <https://www.4basebio.com/investors/analyst-coverage/>.

**For further enquiries, please contact:****4basebio PLC**

Dr. Heikki Lanckriet, CEO  
Nominated Adviser

+44 (0)1223 967 943

+44 (0)20 7213 0880

**Cairn Financial Advisers LLP**

Jo Tuner / Sandy Jamieson / Ed Downes  
Joint Broker

+44 (0)20 7653 4000

**RBC Capital Markets**

Rupert Walford / Max Avison / Kathryn Deegan  
Joint Broker

+44 (0)20 7220 0500

**Cavendish Capital Markets Limited**

Geoff Nash / Nigel Birks

**Notes to Editors****About 4basebio**

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company's objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

**Forward-looking statements**

This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.

---



---



---



---



---